BiotechTube

Lorcaserin

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatic Impairment

Conditions

Hepatic Impairment

Trial Timeline

Aug 1, 2008 → Dec 1, 2008

NCT ID
NCT00828932

About Lorcaserin

Lorcaserin is a phase 1 stage product being developed by Eisai for Hepatic Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT00828932. Target conditions include Hepatic Impairment.

What happened to similar drugs?

3 of 18 similar drugs in Hepatic Impairment were approved

Approved (3) Terminated (5) Active (12)
✅RifaximinBausch HealthApproved
✅Placebo + RifaximinBausch HealthApproved
✅Rifaximin + LactuloseBausch HealthApproved
🔄cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
🔄PhosphatidylcholineSanofiPhase 3
❌oxaliplatin (SR96669) + capecitabine + sorafenibSanofiPhase 3
🔄Givosiran + PlaceboAlnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT04457687Pre-clinicalActive
NCT03552107Pre-clinicalCompleted
NCT02022956Phase 1Completed
NCT00828581Phase 1Completed
NCT00828932Phase 1Completed

Competing Products

20 competing products in Hepatic Impairment

See all competitors
ProductCompanyStageHype Score
ITF2357BiotrialPhase 1
19
GB1211 + PlaceboComac MedicalPhase 1/2
18
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)IdorsiaPhase 1
23
OlomorasibEli LillyPhase 1
29
SimufilamCassava SciencesPhase 1
19
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
40
exatecan mesylateDaiichi SankyoPhase 2
35
DS-3201bDaiichi SankyoPhase 1
29
QuizartinibDaiichi SankyoPhase 1
29
QuizartinibDaiichi SankyoPhase 1
36
PexidartinibDaiichi SankyoPhase 1
29
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
29
BocidelparAstellas PharmaPhase 1
29
fezolinetantAstellas PharmaPhase 1
29
enzalutamideAstellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP2215Astellas PharmaPhase 1
29
BPN14770ShionogiPhase 1
29
S-217622ShionogiPhase 1
29
LemborexantEisaiPhase 1
29